The University of Southampton
University of Southampton Institutional Repository

Will the advent of antileukotriene therapy lead to changes in asthma treatment guidelines?

Will the advent of antileukotriene therapy lead to changes in asthma treatment guidelines?
Will the advent of antileukotriene therapy lead to changes in asthma treatment guidelines?

Leukotrienes are bronchoconstrictor and pro-inflammatory mediators implicated in asthma. Drugs that block leukotriene synthesis or activity are set to become the first major breakthrough in asthma therapy for 25 years. Antileukotriene drugs block bronchoconstriction after challenge with allergen, aspirin or exercise, and in clinical trials in patients with asthma they improve baseline lung function, reduce night-time awakenings, improve daytime symptom scores and halve the number of acute exacerbations. They are likely to be used as oral prophylactic therapy to reduce the dosage of corticosteroids right across the spectrum of asthma severity. Further studies on possible long term anti-inflammatory effects are currently in progress.

1173-8804
167-174
Sampson, Anthony P.
4ca76f6f-ff35-425d-a7e7-c2bd2ea2df60
Corne, Jonathan M.
f2d716a7-31f0-40a3-afb3-d86b850634ee
Holgate, Stephen T.
2e7c17a9-6796-436e-8772-1fe6d2ac5edc
Sampson, Anthony P.
4ca76f6f-ff35-425d-a7e7-c2bd2ea2df60
Corne, Jonathan M.
f2d716a7-31f0-40a3-afb3-d86b850634ee
Holgate, Stephen T.
2e7c17a9-6796-436e-8772-1fe6d2ac5edc

Sampson, Anthony P., Corne, Jonathan M. and Holgate, Stephen T. (1997) Will the advent of antileukotriene therapy lead to changes in asthma treatment guidelines? BioDrugs, 7 (3), 167-174. (doi:10.2165/00063030-199707030-00001).

Record type: Review

Abstract

Leukotrienes are bronchoconstrictor and pro-inflammatory mediators implicated in asthma. Drugs that block leukotriene synthesis or activity are set to become the first major breakthrough in asthma therapy for 25 years. Antileukotriene drugs block bronchoconstriction after challenge with allergen, aspirin or exercise, and in clinical trials in patients with asthma they improve baseline lung function, reduce night-time awakenings, improve daytime symptom scores and halve the number of acute exacerbations. They are likely to be used as oral prophylactic therapy to reduce the dosage of corticosteroids right across the spectrum of asthma severity. Further studies on possible long term anti-inflammatory effects are currently in progress.

This record has no associated files available for download.

More information

Published date: 1997
Additional Information: Copyright: Copyright 2017 Elsevier B.V., All rights reserved.

Identifiers

Local EPrints ID: 455207
URI: http://eprints.soton.ac.uk/id/eprint/455207
ISSN: 1173-8804
PURE UUID: 67aea8d5-09a3-41a5-84f4-2276b102c8ec
ORCID for Anthony P. Sampson: ORCID iD orcid.org/0009-0008-9653-8935

Catalogue record

Date deposited: 15 Mar 2022 17:33
Last modified: 17 Mar 2024 02:43

Export record

Altmetrics

Contributors

Author: Jonathan M. Corne

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×